MODERNA INC

The pact links two big players in the vaccine world that both missed out on the rush to develop and commercialize Covid shots quickly during the pandemic. Amid various setbacks, Sanofi and Novavax ceded tens of billions of dollars in sales to nimble...

The waning of the COVID-19 pandemic is reshaping the healthcare industry once again. Vaccine makers and pharmacy chains are seeing a decline in the number of people getting COVID shots, while makers of at-home rapid tests are going out of business. ...

Data from the second trial comes two months after its flu vaccine generated a strong immune response against influenza A strains, but was inferior to an approved vaccine when compared to the less-prevalent influenza B strain in the first late-stage ...

The potential deal with the U.S. Department of Defense (DoD) would see Moderna's mRNA technology being used to develop a vaccine targeting the Ebola strain responsible for the disease's outbreak in Uganda, the report said.

The vaccine, a mist that is sucked in through the mouth, is being offered for free as a booster dose for previously vaccinated people, according to an announcement on an official city social media account.

Pfizer Chief Executive Officer Albert Bourla , 60, back in August had contacted COVID and had started a course of the company's oral COVID-19 antiviral treatment, Paxlovid.

"We are open, we have the capacity" Bancel said about supplying its mRNA-based shots to the country, declining to say whether Moderna had submitted its vaccine for approval there.

​​​ The EU regulator said Monday that laboratory studies suggest the combination vaccine - which targets both the original COVID-19 virus as well as the omicron subvariants BA.4 and BA.5 - should trigger an effective immune response. The vaccine is ...

Moderna has been studying the so-called bivalent vaccine, which targets both Omicron and the original coronavirus strain to determine if it works better against the variant. Several studies have shown that vaccine immunity starts to wane over time, ...

The U.S.-based vaccine maker will postpone the delivery of some doses initially planned for the second quarter of 2022 to later in the year, the European Commission said in a statement.

The panel will also discuss the process for selecting COVID-19 vaccine strain to address current and emerging variants, the U.S. FDA said.

“We should know about the ability of the current vaccine to provide protection in the next couple of weeks,” Burton said.

Moderna's comments were released in briefing documents ahead of a Thursday meeting of the FDA's outside expert advisers to discuss the booster dose.

Many governments that once relied on vaccines from Sinovac Biotech Ltd. or Sinopharm Group Co Ltd. are now turning to options from the US and Europe instead, as concerns mount about Chinese vaccines’ efficacy against the delta strain and the Western...

Some Moderna shots were temporarily halted in Okinawa on Sunday after foreign materials were discovered in vials and syringes. The health ministry said later needles may have been incorrectly inserted into vials, breaking off bits of the rubber stop...

That compares favorably to data released by rivals Pfizer Inc and BioNTech SE last week in which they suggested their vaccine's efficacy waned around 6% every two months, declining to around 84% six months after the second shot. Both the Moderna and...

The new price for the Pfizer shot was 19.50 euros ($23.15)against 15.50 euros previously, the newspaper said citing to the portions of the contracts seen.